Assenagon Asset Management S.A. Makes New Investment in Integer Holdings Corporation $ITGR

Assenagon Asset Management S.A. bought a new position in Integer Holdings Corporation (NYSE:ITGR - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 51,349 shares of the medical equipment provider's stock, valued at approximately $6,314,000. Assenagon Asset Management S.A. owned 0.15% of Integer at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ITGR. Opal Wealth Advisors LLC purchased a new stake in shares of Integer in the 1st quarter worth about $28,000. AdvisorNet Financial Inc purchased a new stake in shares of Integer in the 1st quarter worth about $28,000. Bessemer Group Inc. grew its position in Integer by 73.1% during the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 125 shares during the last quarter. SVB Wealth LLC purchased a new stake in Integer during the 1st quarter valued at about $35,000. Finally, Headlands Technologies LLC grew its position in Integer by 1,234.8% during the 1st quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider's stock valued at $145,000 after purchasing an additional 1,136 shares during the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Trading Down 0.4%

ITGR stock opened at $103.21 on Wednesday. The firm has a fifty day moving average price of $107.25 and a 200 day moving average price of $114.97. Integer Holdings Corporation has a fifty-two week low of $99.73 and a fifty-two week high of $146.36. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. The firm has a market cap of $3.62 billion, a PE ratio of 45.47, a price-to-earnings-growth ratio of 0.82 and a beta of 1.03.

Integer (NYSE:ITGR - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The business had revenue of $476.00 million during the quarter, compared to analysts' expectations of $464.37 million. During the same period last year, the business posted $1.30 earnings per share. The company's revenue for the quarter was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. Sell-side analysts anticipate that Integer Holdings Corporation will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on ITGR. Raymond James Financial cut their price objective on shares of Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a research report on Friday, July 25th. Wells Fargo & Company cut their price objective on shares of Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Wall Street Zen upgraded shares of Integer from a "hold" rating to a "buy" rating in a research note on Saturday, August 30th. Finally, Truist Financial lowered their target price on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research note on Friday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Integer has an average rating of "Buy" and a consensus price target of $140.25.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.